Combination drugs before surgery for PD-L1-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two drugs given before surgery to shrink tumors in people with a type of lung cancer (non-small cell) that has a specific protein called PD-L1. The goal is to see if this treatment helps remove the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your lung cancer must be a type called non-small cell, with a PD-L1 level of at least 1%.
- Your cancer must not have certain gene changes (EGFR or ALK) and must be considered surgically removable by your doctor.
- You cannot have had any previous cancer treatment like chemotherapy, immunotherapy, or radiation for this cancer.
- You must be willing to have surgery as part of the treatment plan.
- Your overall health must be good, as measured by standard blood tests and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, given before surgery to shrink early-stage NSCLC (stage II to IIIB) that can be removed. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery for stage III lung cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests whether giving a combination of two targeted drugs (tislelizumab and anlotinib) plus standard chemotherapy before and after surgery can help people with early-stage lung cancer. The goal is to see if this approach can shrink the tumor and lower the chance of the cancer coming back.
Hear when a new Resectable Stage II-IIIB NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.